Nektar Therapeutics buy phonebroker
Summary
This prediction ended on 23.03.18 with a price of €82.98. With a performance of -2.42%, the BUY prediction by phonebroker finished with a loss. phonebroker has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Nektar Therapeutics | -1.229% | -1.229% | 139.636% | -89.171% |
iShares Core DAX® | 0.051% | 5.593% | 14.403% | 19.767% |
iShares Nasdaq 100 | 1.808% | 7.445% | 34.917% | 57.237% |
iShares Nikkei 225® | 2.181% | 2.815% | 11.116% | 8.873% |
iShares S&P 500 | 1.040% | 4.975% | 27.631% | 48.786% |
Comments by phonebroker for this prediction
In the thread Nektar Therapeutics diskutieren
phonebroker stimmt dem Sentiment von 'Sell' nicht zu
Kurs kennt nur eine Richtung,
Stopped prediction by phonebroker for Nektar Therapeutics
Nektar Therapeutics
04.10.18
10.10.18
10.10.18